Evidence map›Paper›PMID 41280560›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2025

PARP-targeted molecular imaging for noninvasive diagnosis and surgical guidance in basal cell carcinoma.

Steven H Liang

Abstract readEditorial
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University Atlanta, Georgia 30322, The United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(ADP-Ribose) Polymerase 1 (PARP1) is a key DNA repair enzyme and therapeutic target in cancer, with overexpression observed in several cancers, including basal cell carcinoma (BCC). Conventional diagnostic methods for BCC lack specificity and are invasive, highlighting the need for noninvasive alternatives. PARP-targeted molecular imaging, particularly with fluorescence probes, has shown strong potential for tumor detection and real-time visualization. PARPi-FL, a fluorescent derivative of Olaparib, enables rapid, specific, and high-contrast imaging of BCC in preclinical and

Indexed as

basal cell carcinoma (BCC)fluorescence imagingPoly(ADP-Ribose) Polymerase 1 (PARP1)positron emission tomography (PET)

Identifiers

PMID41280560
PMCPMC12629905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.